AR070045A1 - Forma b cristalina de acido (2r)-(3-amino-2-fluorpropil)fosfinico - Google Patents

Forma b cristalina de acido (2r)-(3-amino-2-fluorpropil)fosfinico

Info

Publication number
AR070045A1
AR070045A1 ARP080105598A ARP080105598A AR070045A1 AR 070045 A1 AR070045 A1 AR 070045A1 AR P080105598 A ARP080105598 A AR P080105598A AR P080105598 A ARP080105598 A AR P080105598A AR 070045 A1 AR070045 A1 AR 070045A1
Authority
AR
Argentina
Prior art keywords
amino
crystalline form
fluorpropil
phosphinic
fluorpropyl
Prior art date
Application number
ARP080105598A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40801457&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR070045(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR070045A1 publication Critical patent/AR070045A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/301—Acyclic saturated acids which can have further substituents on alkyl

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente se refiere a una forma cristalina de ácido (2R)-(3-amino-2-fluorpropil)fosfínico. Además, la presente se dirige al uso de la forma cristalina para el tratamiento de trastornos gastrointestinales, al igual que a composiciones farmacéuticas que comprenden dicha forma cristalina, y a un proceso para la preparacion de la forma cristalina. Reivindicacion 2: El compuesto ácido (2R)-(3-amino-2-fluorpropil)fosfínico, forma B, caracterizado porque proporciona un patron de difraccion de polvo de rayos X que exhibe sustancialmente el siguiente pico con valor d: 2,87 amstrong.
ARP080105598A 2007-12-21 2008-12-19 Forma b cristalina de acido (2r)-(3-amino-2-fluorpropil)fosfinico AR070045A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1576607P 2007-12-21 2007-12-21

Publications (1)

Publication Number Publication Date
AR070045A1 true AR070045A1 (es) 2010-03-10

Family

ID=40801457

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080105598A AR070045A1 (es) 2007-12-21 2008-12-19 Forma b cristalina de acido (2r)-(3-amino-2-fluorpropil)fosfinico

Country Status (8)

Country Link
US (1) US20110034420A1 (es)
EP (1) EP2235027A4 (es)
AR (1) AR070045A1 (es)
CL (1) CL2008003841A1 (es)
PE (1) PE20091310A1 (es)
TW (1) TW200940559A (es)
UY (1) UY31558A1 (es)
WO (1) WO2009082345A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009082344A1 (en) * 2007-12-21 2009-07-02 Astrazeneca Ab Novel process for making (2r)-(3-amino-2-fluoropropyl)phosphinic acid form a

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904507D0 (sv) * 1999-12-09 1999-12-09 Astra Ab New compounds
SE9904508D0 (sv) * 1999-12-09 1999-12-09 Astra Ab New compounds
FR2810824B1 (fr) * 2000-06-26 2003-01-17 Cit Alcatel Dispositif de fixation pour appareil de telecommunication mobile
SE0102057D0 (sv) * 2001-06-08 2001-06-08 Astrazeneca Ab New Salts I
WO2009014490A1 (en) * 2007-07-25 2009-01-29 Astrazeneca Ab Combination of (3-amino-2-fluoropropyl)phosphinic acid and omeprazole for treating tlesr, gerd, and nerd
JP2010534239A (ja) * 2007-07-25 2010-11-04 アストラゼネカ・アクチエボラーグ Ｎｅｒｄの治療のための（３−アミノ−２−フルオロプロピル）ホスフィン酸の使用
WO2009145716A1 (en) * 2008-05-28 2009-12-03 Astrazeneca Ab New pharmaceutical formulation useful in gerd therapy

Also Published As

Publication number Publication date
EP2235027A4 (en) 2011-06-22
UY31558A1 (es) 2009-08-03
US20110034420A1 (en) 2011-02-10
TW200940559A (en) 2009-10-01
WO2009082345A1 (en) 2009-07-02
CL2008003841A1 (es) 2010-04-16
PE20091310A1 (es) 2009-09-30
EP2235027A1 (en) 2010-10-06

Similar Documents

Publication Publication Date Title
NI200800294A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmacéuticas que la contienen.
CO6551760A2 (es) Polco de rifaximina , proceso para prepararlo y composiciones de liberación controlada que contiene dicha rifaeimina útil para obtener un efecto de larga duración
CY1117434T1 (el) Φαρμακευτικες μορφες απιξαμπανης
EA201170053A1 (ru) Способ получения и сушки твердого разагилина в форме основания
AR088755A1 (es) Formas solidas de un inhibidor de disociacion transtiretina
BRPI0603059A (pt) forma cristalina v de agomelatina, um processo para sua preparação e composições farmacêuticas contendo-a
PE20120083A1 (es) Sal monotosilato del compuesto 2-metil-2-[4-(3-metil-2-oxo-8-quinolin-3-il-2, 3-dihidro-imidazo-[4,5-c]-quinolin-1-il)-fenil]-propionitrilo en su forma cristalina a
MX2013012289A (es) Triazolopiridinas.
EP2536736A4 (en) PREPARATION OF 6'-O-SIALYLLACTOSE AND INTERMEDIATE PRODUCTS THEREOF
CO6410279A2 (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
BR112015023705A2 (pt) composto da fórmula (ia) ou um sal, hidrato, solvato ou forma cristalina farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composto e método para síntese do composto da fórmula (ia)
GT200600086A (es) Forma cristalina de gamma-d del clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
PE20140698A1 (es) Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2, 4-diamina
CU20120171A7 (es) Triazolopiridinas sustituidas
AR079957A1 (es) Derivados de acidos grasos de salicilatos composiciones farmaceuticas y uso de los mismos
NZ714273A (en) Pharmaceutical composition comprising the combination of a biocompatible nanoparticle and a compound of interest, preparation and uses thereof
PE20130212A1 (es) Formas polimorficas de st-246 y metodos de preparacion
WO2011023367A3 (en) Bisphosphonate-prodrugs
GT201300064A (es) Monohidrato de derivados de aza-adamantano
UA89905C2 (ru) α КРИСТАЛЛИЧЕСКАЯ ФОРМА АРГИНИНОВОЙ СОЛИ ПЕРИНДОПРИЛА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ЕЕ СОДЕРЖИТ
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
EA200900463A1 (ru) Арипипразола гемифумарат и способ его получения
AR082435A1 (es) Valsartan altamente cristalino
WO2009027736A3 (en) 2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer

Legal Events

Date Code Title Description
FB Suspension of granting procedure